陈明远  教授
中山大学二级教授，一级主任医师，优秀博士生导师。中山大学附属第五医院副院长，鼻咽癌首席专家，鼻咽癌防治中心学科带头人，中山大学肿瘤防治中心华南肿瘤学国家重点实验室独立PI，中国抗癌协会鼻咽癌整合防筛专业委员会主任委员、中国医疗保健国际交流促进会鼻咽癌防治分会副主任委员/秘书长，广东省抗癌协会鼻咽癌专委会主任委员，国家高层次人才“万人计划”领军人才（2019年），科技部“中青年科技创新领军人才” （2018年），教育部“新世纪优秀人才” （2012年），广东省“杰出青年医学人才” （2018年）
。发表通讯/第一作者SCI论文50余篇，影响因子200分以上论著1篇，10分以上论著20余篇，包括Lancet, Lancet Oncology, JCO, JAMA Oncology, Cancer Cell等国际顶级医学期刊。荣获广东省科技进步奖一等奖和中国抗癌协会科技奖一等奖（2023年），获邀在ASCO(2017/2019/2023年), ESMO(2019年)等国际知名肿瘤学术大会做口头发言20余次，研究成果获选2021年度美国临床肿瘤学会ASCO全球17大临床肿瘤学重大进展之一  (当年度中国内地唯一入选)，科研成果被NCCN，ESMO，CACA，CSCO等10余项国际国内权威指南采纳，主编专著2部，获得专利授权20余项

代表作：
1.    Yang Q, Cao SM, Guo L, Hua YJ, Huang PY, Zhang XL, Lin M, You R, Zou X, Liu YP, Xie YL, Wang ZQ, Mai HQ, Chen QY, Tang LQ, Mo HY, Cao KJ, Qian CN, Zhao C, Xiang YQ, Zhang XP, Lin ZX, Li WX, Liu Q, Li JB, Ling L, Guo X, Hong MH, Chen MY. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Eur J Cancer. 2019 Sep;119:87-96. doi: 10.1016/j.ejca.2019.07.007. Epub 2019 Aug 16. PMID: 31425966.
2.    You R, Liu YP, Huang PY, Zou X, Sun R, He YX, Wu YS, Shen GP, Zhang HD, Duan CY, Tan SH, Cao JY, Li JB, Xie YL, Zhang YN, Wang ZQ, Yang Q, Lin M, Jiang R, Zhang MX, Hua YJ, Tang LQ, Zhuang AH, Chen QY, Guo L, Mo HY, Chen Y, Mai HQ, Ling L, Liu Q, Chua MLK, Chen MY. Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 Sep 1;6(9):1345-1352. doi: 10.1001/jamaoncol.2020.1808. PMID: 32701129; PMCID: PMC7378870.
3.    You R, Liu YP, Xie YL, Lin C, Duan CY, Chen DP, Pan Y, Qi B, Zou X, Guo L, Cao JY, Zhang YN, Wang ZQ, Liu YL, Ouyang YF, Wen K, Yang Q, Xie RQ, Li HF, Duan XT, Ding X, Peng L, Chen SY, Liang JL, Feng ZK, Xia TL, Xie RL, Jiang R, Gu CM, Liu RZ, Sun R, Yang X, Liu LZ, Ling L, Liu Q, Ng WT, Hua YJ, Huang PY, Chen MY. Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2023 Mar 18;401(10380):917-927. doi: 10.1016/S0140-6736(23)00269-6. Epub 2023 Feb 23. PMID: 36842439.
4.    You R, Liu YP, Xie YL, Lin C, Duan CY, Chen DP, Pan Y, Qi B, Zou X, Guo L, Cao JY, Zhang YN, Wang ZQ, Liu YL, Ouyang YF, Wen K, Yang Q, Xie RQ, Li HF, Duan XT, Ding X, Peng L, Chen SY, Liang JL, Feng ZK, Xia TL, Xie RL, Jiang R, Gu CM, Liu RZ, Sun R, Yang X, Liu LZ, Ling L, Liu Q, Ng WT, Hua YJ, Huang PY, Chen MY. Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2023 Mar 18;401(10380):917-927. doi: 10.1016/S0140-6736(23)00269-6. Epub 2023 Feb 23. PMID: 36842439.
5.    You R, Liu YP, Lin M, Huang PY, Tang LQ, Zhang YN, Pan Y, Liu WL, Guo WB, Zou X, Zhao KM, Kang T, Liu LZ, Lin AH, Hong MH, Mai HQ, Zeng MS, Chen MY. Relationship of circulating tumor cells and Epstein-Barr virus DNA to progression-free survival and overall survival in metastatic nasopharyngeal carcinoma patients. Int J Cancer. 2019 Nov 15;145(10):2873-2883. doi: 10.1002/ijc.32380. Epub 2019 Jun 10. PMID: 31044420.